The human insulin market has witnessed significant growth over the years, driven by the increasing prevalence of diabetes worldwide. As a crucial hormone for regulating blood sugar levels, insulin is essential for individuals with diabetes to manage their condition effectively.
One of the key factors contributing to the growth of the human insulin market is the rising incidence of diabetes globally. According to the International Diabetes Federation (IDF), approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. This alarming increase in diabetic patients has created a substantial demand for human insulin products.
Moreover, advancements in technology and research have led to the development of various types of human insulin formulations, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins. These innovations have improved treatment options for individuals with diabetes, providing them with more flexibility and better glycemic control.